CD147 (EMMPRIN) and matrix metalloproteinase-2 expression in uterine endometrioid adenocarcinoma

Pathology Research and Practice

Volumn 207, Issue 1, 2011, Pages 30-36

  Stewart, C J R ^a   Crook, M L ^a  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

Author keywords

Adenocarcinoma; CD147; Endometrium; Invasion; MMP2

Indexed keywords

CD147 ANTIGEN; GELATINASE A;

ARTICLE; CANCER CELL; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; EPITHELIUM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; MYOMETRIUM; PROTEIN EXPRESSION; STROMA;

AGED; AGED, 80 AND OVER; ANTIGENS, CD147; AUSTRALIA; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM INVASIVENESS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650243835     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.10.005     Document Type: Article

References (43)

1. Abal M., Llaurado M., Doll A., Monge M., Colas E., Gonzalez M., Rigau M., Alazzouzi H., Demajo S., Castellvi J., Garcia A., Ramon y Cajal S., Xercavins J., Vazquez-Levin M.H., Alameda F., Gil-Moreno A., Reventos J. Molecular determinants of invasion in endometrial cancer. Clin. Transl. Oncol. 2007, 9:272-277.
2. Aglund K., Rauvala M., Puistola U., Angstrom T., Turpeenniemi-Hujanen T., Zackrisson B., Stendahl U. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer - MMP-9 correlates to the grade and the stage. Gynecol. Oncol. 2004, 94:699-704.
3. Amant F., Moerman P., Neven P., et al. Endometrial cancer. Lancet 2005, 366:491-505.
4. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
5. Braundmeier A.G., Fazleabas A.T., Lessey B.A., Guo H., Toole B.P., Nowak R.A. Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium. J. Clin. Endocrinol. Metab. 2006, 91:2358-2365.
6. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 1997, 89:1260-1270.
7. Di Nezza L.A., Misajon A., Zhang J., Jobling T., Quinn M.A., Ostor A.G., Nie G., Lopata L., Salamonsen L.A. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 2002, 94:1466-1475.
8. Duffy M.J., McGowan P.M., Gallagher W.M. Cancer invasion and metastasis: changing views. J. Pathol. 2008, 214:283-293.
9. Freitas S., Meduri G., Le Nestour E., Bausero P., Perrot-Applanat M. Expression of metalloproteinases and their inhibitors in blood vessels in human endometrium. Biol. Reprod. 1999, 61:1070-1082.
10. Goffin F., Munaut C., Frankenne F., Perrier D'Hauterive S., Beliard A., Fridman V., Nervo P., Colige A., Foidart J.M. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium. Biol. Reprod. 2003, 69:976-984.
11. Graesslin O., Cortez A., Fauvet R., Lorenzato M., Birembaut P., Darai E. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann. Oncol. 2006, 17:637-645.
12. Graesslin O., Cortez A., Uzan C., Birembaut P., Quereux C., Darai E. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int. J. Gynecol. Cancer 2006, 16:1911-1917. 637-645.
13. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
14. Honkavuori M., Talvensaari-Mattila A., Soini Y., Turpeenniemi-Hujanen T., Santala M. MMP-2 expression associates with CA125 and clinical course in endometrial carcinoma. Gynecol. Oncol. 2007, 104:217-221.
15. Hu M., Polyak K. Microenvironmental regulation of cancer development. Curr. Opin. Genet. Dev. 2008, 18:27-34.
16. Iacono K.T., Brown A.L., Greene M.I., Saouaf S.J. CD147 immunoglobulin superfamily receptor function and role in pathology. Exp. Mol. Pathol. 2007, 83:283-295.
17. Jodele S., Blavier L., Yoon J.M., DeClerck Y.A. Modifying the soli to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 2006, 25:35-43.
18. John A., Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res. 2001, 7:14-23.
19. Karahan N., Guney M., Baspinar S., Oral B., Kapucuoglu N., Mungan T. Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur. J. Gynaecol. Oncol. 2007, 28:184-188.
20. Kataoka H., Tanaka H., Nagaike K., Uchiyama S., Itoh H. Role of cancer cell-stroma interaction in invasive growth of cancer cells. Hum. Cell 2003, 16:1-14.
21. Landry D., Mai K.T., Senterman M.K., Perkins D.G., Yazdi H.M., Veinot J.P., Thomas J. Endometrioid adenocarcinoma of the uterus with a minimal deviation invasive pattern. Histopathology 2003, 42:77-82.
22. Longacre T., Hendrickson M.R. Diffusely infiltrative endometrial adenocarcinoma: an adenoma malignum pattern of myoinvasion. Am. J. Surg. Pathol. 1999, 23:69-78.
23. Misugi F., Sumi T., Okamoto E., Nobeyama H., Hattori K., Yoshida H., Matsumoto Y., Yasui T., Honda K., Ishiko O. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis. Int. J. Mol. Med. 2005, 16:541-546.
24. Moser P.L., Hefler L., Tempfer C., Neunteufel W., Kieback D.G., Gitsch G. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer. Anticancer Res. 1999, 19:2365-2367.
25. Murray S.K., Young R.H., Scully R.E. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinomas: a study of their frequency, associated diagnostic problems, and prognostic significance. Int. J. Gynecol. Pathol. 2003, 22:324-333.
26. Nabeshima K., Iwasaki H., Koga K., Hojo H., Suzumiya J., Kikuchi M. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol. Int. 2006, 56:359-367.
27. Noguchi Y., Sato T., Hirata M., Hara T., Ohma K., Ito A. Identification and characterization of extracellular matrix metalloproteinase inducer in human endometrium during the menstrual cycle in vivo and in vitro. J. Clin. Endocrinol. Metab. 2003, 88:6063-6072.
28. Orlichenko L.S., Radisky D.C. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin. Exp. Metastasis 2008, 25:593-600.
29. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynecol. Obstet. 2009, 105:103-104.
30. Salvesen H.B., Akslen L.A. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS 2002, 110:673-689.
31. Shaco-Levy R., Sharabi S., Piura B., Sion-Vardy N. MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium. Acta Obstet. Gynecol. Scand. 2008, 87:868-874.
32. Sorosky J.I. Endometrial cancer. Obstet. Gynecol. 2008, 111:436-447.
33. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 2000, 10:415-433.
34. Stewart C.J.R., Brennan B.A., Leung Y.C., Little L. MELF pattern invasion in endometrial carcinoma: association with low-grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology 2009, 41:471-476.
35. Stewart C.J.R., Little L. Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology 2009, 55:91-101.
36. Stewart C.J.R., Crook M.L., Leung Y.C., Platten M. Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands. Mod. Pathol. 2009, 22:725-733.
37. Stewart C.J.R., Crook M.L. Galectin-3 expression in uterine endometrioid adenocarcinoma; comparison of staining in conventional tumor glands and in areas of MELF pattern myometrial invasion. Int. J. Gynecol. Pathol. 2010, 29:555-561.
38. Stewart C.J.R., Amanuel B., Grieu F., Carrello A., Iacopetta B. KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion. J. Clin. Pathol. 2010, 63:604-608.
39. Stewart C.J.R., Crook M.L., Doherty D.A. Micro-anatomical variation in cellular proliferation in endometrial adenocarcinoma, and inverse correlation between Ki-67 and cytokeratin 7 expression. Histopathology 2010, 57:46-54.
40. Talvensaari-Mattila A., Santala M., Soini Y., Turpeenniemi-Hujanen T. Prognostic value of matrix metalloproteinases-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res. 2005, 25:4101-4105.
41. Tang Y., Kesavan P., Nakada M.T., Yan L. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol. Cancer Res. 2004, 2:73-80.
42. Ueda K., Yamada K., Urashima M., Ishibashi Y., Shirai M., Nikaido T., Takahashi H., Okamoto A., Saito M., Yasuda M., Ohkawa K., Tanaka T. Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3. Oncol. Rep. 2007, 17:731-735.
43. Vihinen P., Kahari V.-M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer 2002, 99:157-166.